Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 273 clinical trials
  • 0 views
  • 16 Feb, 2024
  • 4 locations
This is a Study to Evaluate the Safety and Tolerability of the Study Medication ABL001 in Combiation With Irinotecan/Paclitaxel and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 in Combination With Irinotecan/Paclitaxel.

The purpose of this open-label, combination dose escalation, Phase 1b/2a clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of combination therapy with ABL001(NOV1501) and Paclitaxel/Irinotecan .

  • 0 views
  • 05 Aug, 2020
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors

The primary objective is to determine the safety profile of SH3051 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors.

metastasis
liver cancer
carcinoma
liver metastasis
cancer
  • 0 views
  • 05 Aug, 2020
A Trial of ZL-1201 in Subjects With Advanced Cancer

First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer

  • 0 views
  • 16 Feb, 2024
  • 1 location
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors. Additionally, the trial will monitor anti-tumor effects on both injected lesions and distant non-injected deposits.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology

This research consists of two parts: part 1: development of microbiome biomarkers for immuno-oncology part 2: proof-of-concept trial on the fecal microbiota transplantation in patients who are being treated with immunotherapy for advanced solid tumor

hepatitis
gastrointestinal infection
hormone replacement therapy
tuberculosis
international travel
  • 0 views
  • 16 Feb, 2024
  • 1 location
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

stage iv nsclc
dabrafenib
liver metastasis
BRAF
neutrophil count
  • 0 views
  • 16 Feb, 2024
  • 4 locations
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

  • 0 views
  • 20 Jul, 2022
  • 24 locations
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

HER2
advanced malignant solid tumor
international normalized ratio
systemic therapy
fulvestrant
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study of oral tazemetostat in subjects with either advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment.

antibiotics
hemolysis
blood count
acquired immunodeficiency syndrome (aids)
antimicrobials
  • 0 views
  • 16 Feb, 2024
  • 5 locations